Recent Updates — QTIH

QT Imaging Holdings, Inc. filed a Form 8-K to furnish a Letter to Shareholders dated August 18, 2026, containing supplemental product and operational information. The letter highlights first-half 2026 financial results, reporting $14.0 million in revenue, an 116% year-over-year increase, alongside the shipment of 28 Breast Acoustic CT scanners. The company completed a $10 million underwritten public offering in the second quarter and extended its senior secured term loan maturity to March 31, 2029. QT Imaging also announced the relocation of its headquarters and manufacturing operations to a new 22,000-square-foot facility in Petaluma, California, which provides more than 2.5 times the current operational space. Additionally, the company secured regulatory clearances in Saudi Arabia, the UAE, and Israel, and noted the American Medical Association's approval of a Category III CPT code for its technology effective January 1, 2027. QT Imaging Holdings, Inc. operates in the medical device industry, specializing in innovative, radiation-free breast imaging systems.

QT Imaging Holdings reported second-quarter revenue of $7.4 million, a 103% increase year-over-year, driven by the shipment of 15 Breast Acoustic CT scanners. First-half revenue rose 116% to $14.0 million with 28 total units shipped. The company recorded a net loss of $11.1 million ($0.75 per share), including an $8.3 million non-cash loss on debt extinguishment from modifying its Lynrock Lake term loan maturity to March 2029. QT Imaging completed a $10.0 million public offering, expanded its U.S. commercial team with new regional sales vice presidents, and secured regulatory approvals in Israel and Saudi Arabia. The company reaffirmed its full-year 2026 revenue guidance of approximately $39 million. QT Imaging is a medical device company that develops and commercializes radiation-free breast imaging technology.